Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Salute | Prodotti farmaceutici | 725,90 Mrd USD | 87,2x | 1,25 | 804,99 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 23,3% Rialzo | Fai l’upgrade a Pro+ | |
UnitedHealth | NYSE | Salute | Fornitori e servizi sanitari | 499,45 Mrd USD | 34,9x | -0,97 | 542,48 USD | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,8% Rialzo | Fai l’upgrade a Pro+ | |
Novo Nordisk ADR | NYSE | Salute | Prodotti farmaceutici | 379,06 Mrd USD | 28,8x | 1,09 | 85,19 USD | -2,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 21,8% Rialzo | Fai l’upgrade a Pro+ | |
J&J | NYSE | Salute | Prodotti farmaceutici | 363,77 Mrd USD | 26x | -0,43 | 150,38 USD | -1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 9,8% Rialzo | Fai l’upgrade a Pro+ | |
AbbVie | NYSE | Salute | Prodotti farmaceutici | 309,43 Mrd USD | 60,9x | -2,76 | 174,81 USD | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 16,2% Rialzo | Fai l’upgrade a Pro+ | |
Roche Holding ADR | OTC Markets | Salute | Prodotti farmaceutici | 249,38 Mrd USD | 22,6x | -6,4 | 38,94 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 22,1% Rialzo | Fai l’upgrade a Pro+ | |
Roche Holding Participation | OTC Markets | Salute | Prodotti farmaceutici | 249,38 Mrd USD | 22,6x | -6,4 | 309,55 USD | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Merck&Co | NYSE | Salute | Prodotti farmaceutici | 246,51 Mrd USD | 20,3x | 0,12 | 97,45 USD | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24,4% Rialzo | Fai l’upgrade a Pro+ | |
Thermo Fisher Scientific | NYSE | Salute | Attrezzature e forniture medicali | 223,12 Mrd USD | 36,4x | 7,86 | 584,29 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,5% Rialzo | Fai l’upgrade a Pro+ | |
Abbott Labs | NYSE | Salute | Attrezzature e forniture medicali | 220,74 Mrd USD | 16,6x | 0,12 | 127,39 USD | -1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6,1% Rialzo | Fai l’upgrade a Pro+ | |
AstraZeneca PLC | OTC Markets | Salute | Prodotti farmaceutici | 215,49 Mrd USD | 33,2x | 3,36 | 137,21 USD | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
AstraZeneca ADR | NASDAQ | Salute | Prodotti farmaceutici | 215,49 Mrd USD | 33,2x | 3,36 | 69,59 USD | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24,9% Rialzo | Fai l’upgrade a Pro+ | |
Intuitive Surgical | NASDAQ | Salute | Attrezzature e forniture medicali | 204,50 Mrd USD | 88,3x | 3,24 | 574,14 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 11,1% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | OTC Markets | Salute | Prodotti farmaceutici | 204,42 Mrd USD | 11,9x | 0,13 | 102,65 USD | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Novartis ADR | NYSE | Salute | Prodotti farmaceutici | 204,42 Mrd USD | 11,9x | 0,13 | 101,84 USD | -1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12% Rialzo | Fai l’upgrade a Pro+ | |
Danaher | NYSE | Salute | Attrezzature e forniture medicali | 179,02 Mrd USD | 47x | -1,33 | 247,84 USD | -1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12,5% Rialzo | Fai l’upgrade a Pro+ | |
Pfizer | NYSE | Salute | Prodotti farmaceutici | 152,10 Mrd USD | 35,7x | -0,58 | 26,75 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 13,9% Rialzo | Fai l’upgrade a Pro+ | |
Boston Scientific | NYSE | Salute | Attrezzature e forniture medicali | 150,89 Mrd USD | 84x | 1,78 | 102,32 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -1,3% Ribasso | Fai l’upgrade a Pro+ | |
Amgen | NASDAQ | Salute | Prodotti farmaceutici | 150,88 Mrd USD | 35,7x | -0,79 | 280,30 USD | -0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 11,7% Rialzo | Fai l’upgrade a Pro+ | |
Stryker | NYSE | Salute | Attrezzature e forniture medicali | 150,87 Mrd USD | 42,1x | 1,09 | 395,15 USD | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 4% Rialzo | Fai l’upgrade a Pro+ | |
Sanofi ADR | NASDAQ | Salute | Prodotti farmaceutici | 132,38 Mrd USD | 25,5x | -0,55 | 52,97 USD | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 19,1% Rialzo | Fai l’upgrade a Pro+ | |
Essilor International SA | OTC Markets | Salute | Attrezzature e forniture medicali | 123,37 Mrd USD | 51,1x | -14,48 | 135,40 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -10,6% Ribasso | Fai l’upgrade a Pro+ | |
Bristol-Myers Squibb | NYSE | Salute | Prodotti farmaceutici | 119,18 Mrd USD | -16,5x | 0,09 | 58,76 USD | -3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7,1% Rialzo | Fai l’upgrade a Pro+ | |
Medtronic | NYSE | Salute | Attrezzature e forniture medicali | 118,10 Mrd USD | 28,1x | 4,47 | 91,98 USD | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 3,2% Rialzo | Fai l’upgrade a Pro+ | |
Gilead | NASDAQ | Salute | Prodotti farmaceutici | 117,24 Mrd USD | 935,5x | -9,4 | 93,85 USD | -1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 5% Rialzo | Fai l’upgrade a Pro+ | |
Vertex | NASDAQ | Salute | Ricerca medica e biotecnologica | 113,73 Mrd USD | -237,8x | 2,07 | 440,68 USD | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,7% Rialzo | Fai l’upgrade a Pro+ | |
Elevance Health | NYSE | Salute | Fornitori e servizi sanitari | 94,05 Mrd USD | 15,8x | 8,6 | 405,40 USD | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,7% Rialzo | Fai l’upgrade a Pro+ | |
Cigna | NYSE | Salute | Fornitori e servizi sanitari | 85,55 Mrd USD | 28,2x | -0,67 | 302,82 USD | -0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 29,9% Rialzo | Fai l’upgrade a Pro+ | |
CSL | OTC Markets | Salute | Prodotti farmaceutici | 83,50 Mrd USD | 31,5x | 1,55 | 85,23 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,7% Rialzo | Fai l’upgrade a Pro+ | |
HCA | NYSE | Salute | Fornitori e servizi sanitari | 83,38 Mrd USD | 14,9x | 0,86 | 328,70 USD | -1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 16,9% Rialzo | Fai l’upgrade a Pro+ |